Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

We are excited to launch GCTx to broaden the accessibility of cell therapy and advance our pipeline of potential best-in-class treatments in various therapeutic areas starting with gastrointestinal, ...

Getting more effective drugs for patients in need as quickly as possible should be the ultimate reward and objective.

Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety ...

Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints Vaccine candidate based on CureVac's ...

LONDON, UK I 11, 2024 I GSK plc (LSE/NYSE: GSK) today announced that it has completed the primary objective data analysis from the phase II part of ...

GSK has announced that Part II of the Phase I/II TH HSV REC-003 trial of its therapeutic herpes simplex virus (HSV) vaccine candidate, GSK3943104, did not meet its primary efficacy endpoint. The ...

GSK announces phase I/II therapeutic herpes simplex virus vaccine trial fails to meet the study’s primary efficacy objective: London, UK Thursday, September 12, 2024, 09:00 Hrs ...

"Given the unmet medical need and burden associated with genital herpes, innovation in this area is still needed. GSK intends to evaluate the totality of all these data and other studies to progress ...

The study will continue for routine safety monitoring and to generate follow-up data that could offer valuable insights into ...

Berenberg Bank analyst Kerry Holford maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a price target ...